Clinical trial
First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker
NCT00455936 · National Cancer Center, Korea, Other · Completed
Key facts
| NCT number | NCT00455936 |
|---|---|
| Title | First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker |
| Official title | A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung |
| Lead sponsor | National Cancer Center, Korea, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Gefitinib, chemotherapy |
| Enrollment | 315 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Apr 4, 2007 |
| Last update posted | Oct 25, 2010 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: